Argenx SE to Report Half-Year 2025 Financial Results and Second-Quarter Business Update

Argenx SE, a biotechnology company focused on antibody-based therapies for severe autoimmune diseases and cancer, will release its half-year 2025 financial results and second-quarter business update on July 31, 2025.

The company’s stock price has experienced fluctuations, but its market capitalization remains substantial.

Industry Developments

• AstraZeneca’s experimental therapy gefurulimab has demonstrated potential in treating a rare muscle disorder.
• The European Commission has approved a new treatment for adult patients with smouldering multiple myeloma.

These developments are expected to have a positive impact on the biotechnology sector, in which Argenx operates.